GSK's ViiV reports higher adherence with injectable HIV treatment versus daily pills in US study
GSK•GSK’s majority-owned ViiV Healthcare will present US real-world study findings linking an injectable HIV regimen with better adherence and treatment retention than daily oral therapy.
1. Study findings
GSK’s majority-owned ViiV Healthcare will present findings at HIV Glasgow linking Vocabria with Rekambys to better adherence than daily oral HIV therapy. The US real-world study also found patients receiving the injectable regimen were more likely to remain on treatment.
2. Pipeline treatments
Pipeline findings support further evaluation of investigational HIV treatments VH184 and VH499 for potential twice-yearly dosing. Neither treatment is approved.
